Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025)

Dianthus Therapeutics has reported Profit After Tax over the past 8 years, most recently at -$36.8 million for Q3 2025.

  • Quarterly results put Profit After Tax at -$36.8 million for Q3 2025, down 46.31% from a year ago — trailing twelve months through Sep 2025 was -$126.4 million (down 88.49% YoY), and the annual figure for FY2024 was -$85.0 million, down 95.16%.
  • Profit After Tax for Q3 2025 was -$36.8 million at Dianthus Therapeutics, down from -$31.6 million in the prior quarter.
  • Over the last five years, Profit After Tax for DNTH hit a ceiling of -$4.9 million in Q1 2022 and a floor of -$36.8 million in Q3 2025.
  • Median Profit After Tax over the past 4 years was -$13.7 million (2024), compared with a mean of -$17.0 million.
  • Biggest five-year swings in Profit After Tax: fell 4.83% in 2023 and later crashed 169.54% in 2024.
  • Dianthus Therapeutics' Profit After Tax stood at -$10.1 million in 2022, then dropped by 4.83% to -$10.6 million in 2023, then plummeted by 169.54% to -$28.5 million in 2024, then fell by 29.13% to -$36.8 million in 2025.
  • The last three reported values for Profit After Tax were -$36.8 million (Q3 2025), -$31.6 million (Q2 2025), and -$29.5 million (Q1 2025) per Business Quant data.